SCHEMBL5636741

SCHEMBL5636741

Fc1cccc(-c2cc3c4c(c2)[C@@H]2CNCC[C@@H]2N4CCO3)c1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 13/20 0.48
HTR2A P28223 11/20 0.41
HTR2B P41595 3/20 0.41
DRD2 P14416 4/20 0.39
HTR1A P08908 1/20 0.36
DRD4 P21917 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
HTR6 P50406 2/20 0.36
KDM4C Q9H3R0 2/20 0.33
PGR P06401 1/20 0.32
KCNH2 Q12809 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636261 0.94 HTR2C (0.52) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5638459 0.91 HTR2C (0.45) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5636979 0.89 HTR2C (0.46) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5637652 0.88 HTR2C (0.44) HTR2CHTR2AHTR2BDRD2HTR6
SCHEMBL5636911 0.87 HTR2C (0.47) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5636052 0.84 HTR2C (0.52) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5637941 0.84 HTR2C (0.45) HTR2CHTR2AHTR2BDRD2PGR
SCHEMBL5639106 0.84 HTR2C (0.41) HTR2CHTR2AHTR2BHTR1APGR
SCHEMBL5637209 0.83 HTR2C (0.42) HTR2CHTR2AHTR2BDRD2HTR1A
SCHEMBL5637783 0.82 HTR2C (0.49) HTR2CHTR2AHTR2BDRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed